Enzon Pharmaceuticals received approval from the FDA for its sBLA for Oncaspar, an oncology product for use as a component of a multi-agent chemotherapeutic regimen for the first-line treatment of patients with acute lymphoblastic leukemia (ALL). Oncaspar had previously been indicated for patients with ALL who require L-asparaginase in their treatment, but developed hypersensitivity to the native forms. The FDA approved the new first-line indication for Oncaspar based on data from two studi...